dard OS extrapolation methods which fit 'traditional' parametric survival distributions to patient-level data, two different methods were explored in the modelling of OS beyond the trial duration (55 months) for the novel immunotherapy ipilimumab. In the first approach, the hazard rate from the Kaplan-Meier (KM) curve between 24 and 36 months (before reaching a plateau) was used to extend the curve. In the second approach, different parametric curves were fitted to the period of 18 months onwards. Akaike's Information Criterion (AIC) was used to determine the best fit curve. RESULTS: When compared to standard OS extrapolation methods, both methods exhibited a better visual fit to the data. Both approaches allow the hazard of the extrapolated tail to be based on a section of the KM curve that is more appropriate in describing the long-term survival of these patients. The hazard rate approach does not allow for a formal comparison with AIC, but allows extrapolation in line with the clinical interpretation. The 'parametric curves' approach allows for a statistically better fit with the patient level data using conventional AIC criteria. Both methods are in line with long-term observations of immunotherapy. CONCLUSION: For novel cancer therapies whose KM curves are not well described by standard survival distributions, other methods of extrapolation should be explored in conjunction with an understanding of the clinical rationale. In this case study, two alternatives are presented that describe the OS of immunotherapy patients in a more suitable way.
OBJECTIVES:
The aim of this study was to investigate whether broadening the evaluative space in an economic evaluation would lead to other outcomes, and hence policy recommendations. METHODS: Two discrete choice experiments (DCE) were conducted in a population of patients who had been treated for varicose vein disease (Nϭ390) either by foam sclerotherapy or surgical stripping. In the Health DCE the treatments were described in terms of health outcomes attributes only (based on the EQ5D dimensions). In the Extended DCE the treatments were described in terms of the same health outcomes attributes and other aspects (Waiting time, Probability of retreatment and Nature of treatment). The differences in the levels were collected in a clinical trial and entered into the preference models to calculate the differnce in utility between those treatments. The ⌬U in both models was standardised on a [-1,1] scale. The incremental costs of foamsclerotherapy versus surgical stripping, as observed in the clinical trial, amounted to -€1123. RESULTS: All attributes were statistically significant, except for Waiting time and Probability of retreatment. The relative importances and the ranks of the health attributes differed between the models. The patients preferred surgical treatment if only health outcomes were considered, while the patients preferred dermatological treatment if also aspects beyond health outcomes were considered in the choice: ⌬Uhealthϭ-0.0109; ⌬Uextendedϭ0.3971. When incremental utility was based on health outcomes only alone, the incremental cost-utility ratio was €103,027. When incremental utility was based broader outcomes, the incremental utility ratio indicated dominance. CONCLUSIONS: The results suggest that recommendation for policy would changed if not only health outcomes but also broader outcomes are considered. The results confirm that a restriction to health outcomes in the (economic) evaluation of health care leads to the maximization of health, but not necessarily to the maximization of benefit in a broader sense.
PODIUM SESSION III: FLOATING THRESHOLDS AND BY PASSES: RISK SHARING AND PATIENT ACCESS

RS1 LITERATURE REVIEW ON PATIENT ACCESS SCHEMES, FLEXIBLE PRICING SCHEMES AND RISK SHARING AGREEMENTS FOR MEDICINES
Puig-Peiró R, Mestre-Ferrandiz J, Sussex J, Towse A Office of Health Economics, London, UK OBJECTIVES: To identify existing knowledge about the costs and benefits, assessed either quantitatively or qualitatively, of performance based reimbursement, risk sharing schemes, patient access schemes, and flexible pricing schemes for pharmaceuticals. METHODS: A systematic literature review was conducted using PubMed for the period January 2008 -April 2011. The terms "risk sharing", "flexible pricing", "patient access schemes", and "performance-based reimbursement" were searched in titles and abstracts. RESULTS: The search provided 62 records and after screening the number was reduced to 31. After full assessments of these studies, a total of 24 formed the basis of the review. More than 40 per cent of the publications referred to the Multiple Sclerosis Risk Sharing Scheme implemented in the UK since 2002. The review did not identify any cost benefit analysis evaluating the overall economic impact of schemes in monetary terms. All studies discussed costs and benefits qualitatively and in some cases, when known, some costs were reported. Schemes' key stakeholders -health service employees, companies, regulators -bear different costs and benefits and conflicting incentives may arise. Costs and benefits widely vary depending on the characteristics of the scheme. CONCLUSIONS: There is lack of consensus on the welfare consequences of the schemes and their social desirability. Identified benefits are countered by significant costs and the overall balance remains unclear. Further research is necessary: a) to assess in a transparent way to what extent the transactional costs and administrative burden are shared between payers and pharmaceutical companies, as they constitute an important barrier for the implementation of the schemes, and b) to aid design of a successful Value Based Pricing system for new medicines in the UK, given the similar principles that underpin outcome-based schemes where prices are set to match "real world" NHS value in practice.
RS2
COST-EFFECTIVENESS OF END-OF-LIFE, LIFE-EXTENDING INTERVENTIONS: NICE'S COST-EFFECTIVENESS THRESHOLD EXPLORED
Hamerslag L, Haynes S, Kusel J, Costello S Costello Medical Consulting Ltd, Cambridge, UK OBJECTIVES: It is widely recognised that the National Institute for Health and Clinical Excellence (NICE) in the UK employs cost-effectiveness thresholds in health technology appraisal decision-making. This incremental cost-effectiveness ratio (ICER) threshold has been topic of much debate and is estimated to lie around £30,000 per quality-adjusted life-year (QALY) gained. In December 2008, NICE approved supplementary advice to reconsider this threshold for life-extending, endof-life interventions. This policy applies to treatments indicated for small patient populations with life expectancies of usually under 24 months, that typically prolong survival by at least 3 months. The aim of this study was to explore NICE's increased ICER threshold when end-of-life conditions are taken into account. METHODS: All NICE technology appraisals issued between December 2008 and June 2011 were reviewed. The appraisals in which end-of-life considerations applied were identified and ICERs from these appraisals were extracted. RESULTS: In total, 53 single technology appraisals were published in the timeframe considered; of these, only 13 fulfilled the end-of-life criteria, all concerning treatments for cancer. The final ICERs of these 13 interventions ranged from £31,800 to £68,000, although 10 out of 13 manufacturers employed patient access schemes to lower these values. Both the highest ICER that was approved and the lowest ICER that was not approved were £49,300 per QALY gained. Interestingly, both of these appraisals concerned interventions for the treatment of advanced renal cell carcinoma, implying that other factors must have been taken into account by NICE to reach this judgement. CONCLUSIONS: Cost-effectiveness seems to be the most important criterion for NICE in their health technology appraisals. For end-of-life, life-extending treatments, the cost-effectiveness threshold appears to lie around £50,000 per QALY. However, review of individual appraisals shows that other factors such as uncertainty in the estimates and unmet need are also taken into account in NICE's decision-making. gory outcome variable was used, defined as the decision to 'recommend', 'restrict' or 'not recommend' a technology. Multivariate analyses were conducted to assess the relative contribution of the explanatory variables on coverage decisions both within and between HTA bodies. RESULTS: Different combinations of clinical/economic evidence, process and socio-economic factors drive HTA coverage decisions by NICE, SMC, CVZ and HAS. In addition, the same factor may behave differently according to the nature of the coverage decision. The analysis further suggests there is a significant difference between HTA bodies in the probability of reaching a 'restrict' or 'not recommend' decision outcome relative to a 'recommend' outcome, adjusted for evidence, process and context factors. CONCLUSIONS: This analysis contributes to the understanding of factors driving HTA coverage decisions by examining multiple European HTA bodies, enhancing the comprehensiveness of the factors examined through descriptive and multivariate analyses and by identifying and weighting the key drivers of the coverage decisions made by the four HTA bodies between 2004 and 2009. This research further provides relevant insights to variation among HTA bodies in the determination of patient access to pharmaceuticals, and implications for collaboration between European HTA bodies.
RS4 THE INTERIM CANCER DRUGS FUND -HOW TO NOT SPEND £50 MILLION
Timm B, Brooks-Rooney C, Hamerslag L, Costello S Costello Medical Consulting, Cambridge, UK OBJECTIVES: The Cancer Drugs Fund (CDF) was established in April 2011 by the UK government, with a pledge of £200 million additional funding for each of the next 3 years to increase patient access to high cost oncology drugs in England. As an interim measure, £50 million was distributed between the 10 strategic health authorities (SHAs) in England to cover the 6 months from October 2010 to March 2011. This research aims to identify how the interim CDF (ICDF) was spent, and to discuss how this could impact utilization of the CDF. METHODS: Data regarding the total funding allocated to each SHA from the ICDF and how much of this money had been spent by March 31, 2011 were obtained from SHA websites. Missing data were accessed through freedom of information requests. RESULTS: Overall, there were over 2700 applications to the fund, with an average approval rate of 91%. Over the 6 month period covered by the ICDF, approximately £21 million was spent across the 10 SHAs in England; this constituted 42% of the £50 million allocated. There was significant variation in the amount spent by each SHA; the highest under-spend was in the South West, where 75% of funds remained unallocated. Several SHAs reported the forecasted costs for continuing treatment beyond March 2011; these costs were incurred in the 2011/12 financial year and therefore were not covered by the ICDF. Remaining budget is expected to be reclaimed by the Department of Health. CONCLUSIONS: It is clear that there was a significant under-spend of the ICDF by all SHAs. It is concerning that many funding applications were rejected, despite the fact that almost half of the funds remained unallocated. Steps need to be taken to ensure more effective use of the CDF and to minimise the risk of regional variations in drug access.
POSTER SESSION I SELECTED HEALTH CARE TREATMENT STUDIES
Medical Device/Diagnostics -Clinical Outcomes Studies
PMD1
ND-YAG LASER INCIDENCE RATE COMPARISON OF THREE MONOFOCAL INTRAOCULAR LENSES (IOL) 36 MONTHS AFTER CATARACT SURGERY IN FRANCE
Lafuma A 1 , Coulomb S 2 , Robert J 2 , Berdeaux G 3 1 CEMKA-EVAL, Bourg la Reine, France, 2 Cemka Eval, Bourg la Reine, France, 3 Alcon France, Rueil-Malmaison, France OBJECTIVES: The aim of this study was to compare the 36-month Nd-Yag laser (a treatment of posterior capsular opacification, the most frequent complication of cataract surgery) incidence rate of three monofocal IOLs: Acrysof SN60WF (Alcon), Akreos AO-MI-60 (Baush&Lomb) and Hoya YA-60BB (Hoya). METHODS: This is a retrospective study conducted at 3 French sites. Each centre implanted at least two of the above IOLs. Patients had to have uncomplicated cataract surgery with at least 2 years of follow-up. Patients implanted with one of the above IOLs were picked up at random from the surgery theatre registry. Medical data were retrieved from patient charts. 36-months post surgical data were obtained from the surgeon's medical files and from other ophthalmologists, if involved in post-surgical care. Time to Nd:Yag laser analysis was carried out using Kaplan-Meier survival curves. Confounding variable imbalances were adjusted with a stepwise Cox model. The statistical unit is the eye. RESULTS: 126 eyes were implanted with Acrysof, 89 with Akreos and 85 with Hoya. Patients with Acrysof were younger (72.1, 76.4 and 75.2 years; Pϭ0.0007). The sex ratio was 4 males: 6 females. Patient follow-up was longer in the Hoya eyes (27.8, 20 .3 and 32.1 months; Pϭ0.002). Eyes implanted with Acrysof had 1.68 times less Nd-Yag laser than Hoya (Pϭ0.06) and 3.43 times less than Akreos (PϽ0.0001). The results remained unchanged when the analysis was restricted to the events occurring during the first 36 months (HRϭ2.20; Pϭ0.009; HRϭ3.67; PϽ0.0001, respectively). Adjusting for confounding variable unbalances did not change the results. CONCLUSIONS: This analysis conducted at 36 months suggests that following usual surgical practice, Acrysof eyes had significantly less Nd-Yag laser capsulotomy than those implanted with Hoya and Akreos. Consequently, Acrysof eyes were less exposed to Nd-YAG laser complications and experienced lower post-surgical treatment costs.
PMD2 CLINICAL DECISION RULES FOR ADULTS WITH MINOR HEAD INJURY: A SYSTEMATIC REVIEW
Harnan SE, Pickering A, Pandor A, Goodacre SW The University of Sheffield, Sheffield, South Yorkshire, UK OBJECTIVES: A small number of cases of minor head injury deteriorate, resulting in serious injury or death. Computed Tomography (CT) identify intracranial injuries, but because it carries a cost and its own health risk, it should be limited to those most likely to have an injury. Clinical decision rules aim to identify these patients. There are many such rules, but it is unclear how their diagnostic accuracy compare. This study aimed to systematically identify clinical decision rules for adults with minor head injury and compare the estimated diagnostic accuracy. METHODS: Several key electronic bibliographic databases (biomedical, scientific and grey literature), were searched from inception to March 2010. Retrieved citations were considered for inclusion by at least two independent reviewers. Cohort studies that described a clinical decision rule to identify adults with minor head injury (GCS 13-15) at risk of intracranial injury or injury requiring neurosurgical intervention were included in the review. Data was extracted by one reviewer and checked by a second. Studies were quality assessed using the QuADAS tool. RESULTS: Twenty-two relevant studies were identified. No study satisfied all quality assessment items. Heterogeneity amongst patient selection criteria, outcome definitions, and reference standards was identified. The Canadian CT Head Rule (CCHR) high-risk criteria had sensitivity of 99-100% with specificity of 48-77% for injury requiring neurosurgical intervention. Other rules, such as New Orleans criteria, NEXUS II, NCWFNS and SIGN produce similar sensitivities but with lower and more variable specificity values. CONCLUSIONS: The most widely researched decision rule is the CCHR, which has consistently shown high sensitivity for identifying injury requiring neurosurgical intervention, with an acceptable specificity to allow considered use of cranial CT. No other decision rule has been validated as widely, or demonstrated similarly acceptable results. However, its exclusion criteria mean it may make it difficult to apply universally.
PMD3 BIOCHEMICAL MARKERS FOR THE IDENTIFICATION OF INTRACRANIAL INJURY FOLLOWING MINOR HEAD INJURY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Pickering A, Fitzgerald P, Harnan SE, Pandor A, Goodacre SW The University of Sheffield, Sheffield, South Yorkshire, UK OBJECTIVES: Minor head injury (MHI) can lead to deterioration, severe injury and death in a small number of cases. Using Computed Tomography (CT) scans on all those with MHI would result in large numbers receiving an unnecessary dose of radiation. Biochemical markers may be useful in reducing the number of scans. This study aimed to systematically identify and synthesize data estimating the diagnostic accuracy of biochemical markers for intracranial injury on CT in patients with MHI. METHODS: Key databases including MEDLINE, EMBASE & CINAHL were searched for potentially relevant literature. Studies reporting a cohort of more than 20 patients, with more than 50% having suffered a MHI (GCS 13-15), and which tested the diagnostic accuracy of a biochemical marker for intracranial or neurosurgical injury were included. Quality was assessed using the QUality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. Meta-analysis was used to estimate pooled sensitivity, specificity and likelihood ratios. RESULTS: Of the 12 included papers, nine provided diagnostic data on protein S100B only, one for Neuron-Specific Enolase (NSE) only, one for other markers and one study for both S100B and NSE levels. Data was only extracted and synthesized from S100B studies. Bayesian meta-analysis of these pooled data for 2442 adult subjects gave sensitivity of 96.8% (95% High Density Region (HDR), 93.8 to 98.6%) and specificity of 42.5% (95% HDR, 31.0 to 54.2%) with a negative likelihood ratio of 0.076 (95% HDR, 0.031 to 0.156). CONCLUSIONS: Evidence to support the addition of protein S100B as a triage tool for CT in MHI patients within three hours of injury is promising. Whilst the quality of studies is good, results are heterogeneous. S100B has the potential to be used in conjunction with a clinical decision rule. The marker therefore needs further testing as a component within such a diagnostic pathway.
PMD4 EXPERT ELICITATION TO POPULATE EARLY HEALTH ECONOMIC MODELS OF MEDICAL DIAGNOSTIC DEVICES IN DEVELOPMENT
Haakma W 1 , Bojke L 2 , Steuten L 1 , Ijzerman M 1 1 University of Twente, Enschede, The Netherlands, 2 University of York, York, Heslington, UK OBJECTIVES: During the development of new diagnostic and therapeutic devices, it is desirable to indicate their cost-effectiveness and to establish their potential clinical value to guide further research. In these early stages of development, however, there are usually limited or no clinical data available. In this study, expert elicitation was used to estimate uncertain priors of the diagnostic performance of a new imaging technology, i.e. Photo Acoustic Mammography (PAM). We compared PAM to Magnetic Resonance Imaging (MRI), in the detection of breast cancer. METHODS: Expert elicitation was used as a method to formulate the knowledge and beliefs of experts about the future performance of PAM and to quantify this information into probability distributions. 18 radiologists estimated the true positive rate and true negative rate based on existing MRI data and specified the mode, the lower, and the upper boundaries (95% credible interval). An overall probability density function (PDF) was determined using the linear opinion pooling method in which weighting is applied to reflect the performance of individual experts. RESULTS: The overall PDF indicated a sensitivity ranging from 58.9% to 85.1%, with a mode of 73.3%. The specificity ranges from 52.2% to 77.6%, with a mode of 66.5%. Experts expressed difficulties making the estimations, as there is not sufficient A244
